[{"from": "human", "value": "Could you provide a description of this molecule? [C][C][=C][C][=Branch2][Ring1][=Branch1][=C][C][=Branch1][P][=C][Ring1][=Branch1][O][C][Branch1][C][C][Branch1][C][C][C][=Branch1][C][=O][O][C][/C][=C][/C][=Branch1][C][=O][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][S][C]"}, {"from": "gpt", "value": "The molecule is a multimodal and pluripotent medication for treatment of atherogenic dyslipidemia for an overweight patient with or without diabetes. It is an oral treatment that acts on the 3 sub-types of PPAR (PPARa, PPARg, PPARd) with a preferential action on PPARa. As of February 2016, elafibranor has completed 8 clinical trials and a phase III is in progress."}]